Cocrystal Pharma completes dosing in norovirus Phase 1b trial

September 9, 2026 7:00 AM

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that the last subject has been dosed in its Phase 1b norovirus human challenge ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found